These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29693245)

  • 1. Developing anti-HER2 vaccines: Breast cancer experience.
    Al-Awadhi A; Lee Murray J; Ibrahim NK
    Int J Cancer; 2018 Nov; 143(9):2126-2132. PubMed ID: 29693245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
    Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
    Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.
    Arab A; Yazdian-Robati R; Behravan J
    Arch Immunol Ther Exp (Warsz); 2020 Jan; 68(1):2. PubMed ID: 31915932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-HER2 vaccines: new prospects for breast cancer therapy.
    Ladjemi MZ; Jacot W; Chardès T; Pèlegrin A; Navarro-Teulon I
    Cancer Immunol Immunother; 2010 Sep; 59(9):1295-312. PubMed ID: 20532501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2-Based Immunotherapy for Breast Cancer.
    Cui N; Shi J; Yang C
    Cancer Biother Radiopharm; 2018 Jun; 33(5):169-175. PubMed ID: 29874101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical development of vaccines for HER2
    Costa RLB; Soliman H; Czerniecki BJ
    Cancer Treat Rev; 2017 Dec; 61():107-115. PubMed ID: 29125981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of HER2/ neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients.
    Azuma K; Shichijo S; Shomura H; Matsueda S; Fujii T; Itoh K
    Breast Cancer Res Treat; 2004 Jul; 86(1):19-29. PubMed ID: 15218358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition.
    Correa I; Plunkett T
    Breast Cancer Res; 2001; 3(6):399-403. PubMed ID: 11737893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
    Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
    Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.
    Morse MA; Hobeika A; Osada T; Niedzwiecki D; Marcom PK; Blackwell KL; Anders C; Devi GR; Lyerly HK; Clay TM
    J Transl Med; 2007 Sep; 5():42. PubMed ID: 17822557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer vaccines targeting the HER2/neu oncogenic protein.
    Disis ML; Schiffman K
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):12-20. PubMed ID: 11774201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.
    Gall VA; Philips AV; Qiao N; Clise-Dwyer K; Perakis AA; Zhang M; Clifton GT; Sukhumalchandra P; Ma Q; Reddy SM; Yu D; Molldrem JJ; Peoples GE; Alatrash G; Mittendorf EA
    Cancer Res; 2017 Oct; 77(19):5374-5383. PubMed ID: 28819024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing HER2 vaccines.
    Foy TM; Fanger GR; Hand S; Gerard C; Bruck C; Cheever MA
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):53-61. PubMed ID: 12138398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boosting anti-HER2 CD4 T-helper responses in HER2 expressing ductal carcinoma in situ.
    Nocera NF; Lee MC; Czerniecki BJ
    Future Oncol; 2017 Jul; 13(17):1459-1462. PubMed ID: 28766964
    [No Abstract]   [Full Text] [Related]  

  • 16. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.
    Mittendorf EA; Storrer CE; Shriver CD; Ponniah S; Peoples GE
    Ann Surg Oncol; 2006 Aug; 13(8):1085-98. PubMed ID: 16865596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer.
    Conti L; Bolli E; Di Lorenzo A; Franceschi V; Macchi F; Riccardo F; Ruiu R; Russo L; Quaglino E; Donofrio G; Cavallo F
    Cancer Immunol Res; 2020 Aug; 8(8):1039-1053. PubMed ID: 32532810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer.
    Bartolacci C; Andreani C; Curcio C; Occhipinti S; Massaccesi L; Giovarelli M; Galeazzi R; Iezzi M; Tilio M; Gambini V; Wang J; Marchini C; Amici A
    Cancer Immunol Res; 2018 Dec; 6(12):1486-1498. PubMed ID: 30327365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
    Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
    Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunizing against breast cancer: a new swing for an old sword.
    Curigliano G; Locatelli M; Fumagalli L; Goldhirsch A
    Breast; 2009 Oct; 18 Suppl 3():S51-4. PubMed ID: 19914543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.